# Effectiveness of GlaxoSmithKline Biologicals S.A's Meningococcal Group B and Combined ABCWY Vaccines in Healthy Adolescents and Young Adults

> **NCT04502693** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 3657 (actual)

## Conditions studied

- Infections, Meningococcal

## Interventions

- **COMBINATION_PRODUCT:** rMenB+OMV NZ vaccine
- **BIOLOGICAL:** Meningococcal Groups A, C, W and Y Conjugate Vaccine (MenACWY)
- **COMBINATION_PRODUCT:** Placebo
- **COMBINATION_PRODUCT:** MenABCWY-1
- **COMBINATION_PRODUCT:** MenABCWY-2
- **COMBINATION_PRODUCT:** MenABCWY-3

## Key facts

- **NCT ID:** NCT04502693
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-08-14
- **Primary completion:** 2022-09-13
- **Final completion:** 2022-09-13
- **Target enrollment:** 3657 (ACTUAL)
- **Last updated:** 2024-03-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04502693

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04502693, "Effectiveness of GlaxoSmithKline Biologicals S.A's Meningococcal Group B and Combined ABCWY Vaccines in Healthy Adolescents and Young Adults". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04502693. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*